Dual antiplatelet therapy, with clopidogrel added to aspirin, presents a major advance with clear benefit in managing patients with acute myocardial infarction, according to a US expert.1 Sabatine, from the Thrombolysis in Myocardial Infarction (TIMI) Study Group, was commenting on findings from COMMIT — the ClOpidogrel and Metoprolol in Myocardial Infarction Trial; also known as the Second Chinese Cardiac Study.2,3
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
Correspondence:
Online responses are no longer available. Please refer to our instructions for authors page for more information.